Immunotherapies are more effective and promising for some tumor patients than others, and our study therefore suggested that c-MET/EGFR could be an important contributor to those less sensitive to CRC immunotherapy compared to other cancer types as reported in a previous study (Banerjea et al., 2005), hence providing a rationale for a combination of c-MET/EGFR antagonists and immunotherapy in CRC. The gene discussed is EGFR; the disease is cancer.